Ecoclimber
Senior Member
- Messages
- 1,011
Sci Transl Med. 2014 Jun 18;6(241):241ra78.
In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response.
Kasagi S1, Zhang P1, Che L1, Abbatiello B1, Maruyama T1, Nakatsukasa H1, Zanvit P1, Jin W1, Konkel JE1, Chen W2.
Abstract
Harnessing regulatory T (Treg) cells is a promising approach for treating autoimmune disease. However, inducing antigen-specific Treg cells that target inflammatory immune cells without compromising beneficial immune responses has remained an unmet challenge.
We developed a pathway to generate autoantigen-specific Treg cells in vivo, which showed therapeutic effects on experimental autoimmune encephalomyelitis and nonobese diabetes in mice. Specifically, we induced apoptosis of immune cells by systemic sublethal irradiation or depleted B and CD8(+) T cells with specific antibodies and then administered autoantigenic peptides in mice with established autoimmune diseases.
We demonstrated mechanistically that apoptotic cells triggered professional phagocytes to produce transforming growth factor-β, under which the autoantigenic peptides directed naïve CD4(+) T cells to differentiate into Foxp3(+) Treg cells instead of into T effector cells in vivo.
These antigen-specific Treg cells specifically ameliorated autoimmunity without compromising immune responses to bacterial antigen.
We have thus successfully generated antigen-specific Treg cells with therapeutic activity toward autoimmunity.
The findings may lead to the development of antigen-specific Treg cell-mediated immunotherapy for multiple sclerosis and type 1 diabetes and also other autoimmune diseases.
In vivo-generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response.
Kasagi S1, Zhang P1, Che L1, Abbatiello B1, Maruyama T1, Nakatsukasa H1, Zanvit P1, Jin W1, Konkel JE1, Chen W2.
Abstract
Harnessing regulatory T (Treg) cells is a promising approach for treating autoimmune disease. However, inducing antigen-specific Treg cells that target inflammatory immune cells without compromising beneficial immune responses has remained an unmet challenge.
We developed a pathway to generate autoantigen-specific Treg cells in vivo, which showed therapeutic effects on experimental autoimmune encephalomyelitis and nonobese diabetes in mice. Specifically, we induced apoptosis of immune cells by systemic sublethal irradiation or depleted B and CD8(+) T cells with specific antibodies and then administered autoantigenic peptides in mice with established autoimmune diseases.
We demonstrated mechanistically that apoptotic cells triggered professional phagocytes to produce transforming growth factor-β, under which the autoantigenic peptides directed naïve CD4(+) T cells to differentiate into Foxp3(+) Treg cells instead of into T effector cells in vivo.
These antigen-specific Treg cells specifically ameliorated autoimmunity without compromising immune responses to bacterial antigen.
We have thus successfully generated antigen-specific Treg cells with therapeutic activity toward autoimmunity.
The findings may lead to the development of antigen-specific Treg cell-mediated immunotherapy for multiple sclerosis and type 1 diabetes and also other autoimmune diseases.